For breast cancer, the PPARγ agonist GW7845 can inhibit N-nitroso-N-methylurea-induced breast cancer in rats [136] and treatment with troglitazone can also alleviate breast cancer induced by 7,12-dimethylbenz[a]anthracene (DMBA) in mice [137]. Here, PPARG is linked to breast carcinoma.